MedTrace Logo

Nasal Resveratrol and Wheezing Episodes in Preschool Children

NCT04689412 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-12-30

No results posted yet for this study

Summary

As most of the upper airways infections (UAI) leading to wheezing are secondary to viral triggers, the possible antinflammatory and antiviral role of resveratrol has been suggested in several studies, both in vitro and in vivo. However, its efficacy has been studied only when evaluating upper respiratory symptoms.

With the aim to define new approaches in patients with recurrent wheezing triggered by UAI we have performed a prospective observational study to evaluate the efficacy of a short-course of intranasal resveratrol, administered for 7 days at the beginning of UAI, when compared to standard nasal lavage with 0.9% saline solution, in terms of reduction in wheezing episodes.

Conditions

  • Wheezing
  • Upper Respiratory Tract Infections

Interventions

DRUG

Resveratrol

Nasal administration of resveratrol

Sponsors & Collaborators

  • University Of Perugia

    lead OTHER

Eligibility

Min Age
3 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2019-03-31
Completion
2019-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04689412 on ClinicalTrials.gov